Victory Capital Management Inc. Buys 3,488 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Victory Capital Management Inc. raised its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 76.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 8,057 shares of the company’s stock after acquiring an additional 3,488 shares during the period. Victory Capital Management Inc.’s holdings in TransMedics Group were worth $502,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Principal Financial Group Inc. lifted its stake in shares of TransMedics Group by 260.1% in the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after purchasing an additional 146,115 shares during the period. State of Michigan Retirement System bought a new position in shares of TransMedics Group in the 4th quarter worth approximately $6,734,000. Public Sector Pension Investment Board bought a new position in shares of TransMedics Group in the 3rd quarter worth approximately $11,079,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of TransMedics Group by 665.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock worth $11,716,000 after purchasing an additional 64,872 shares during the period. Finally, Baillie Gifford & Co. lifted its stake in shares of TransMedics Group by 14.9% in the 4th quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock worth $16,824,000 after purchasing an additional 34,947 shares during the period. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Up 0.3 %

Shares of TMDX opened at $69.05 on Friday. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The company has a 50 day simple moving average of $68.12 and a two-hundred day simple moving average of $91.06. The firm has a market cap of $2.32 billion, a P/E ratio of 73.46 and a beta of 2.12.

Analyst Ratings Changes

Several brokerages have recently weighed in on TMDX. Canaccord Genuity Group reiterated a “buy” rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Oppenheimer reiterated an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. Robert W. Baird reduced their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Finally, Piper Sandler reduced their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.